Taxoprexin Pivotal Studies Begin in Melanoma and Pancreatic Cancer

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 11 No 11
Volume 11
Issue 11

KING OF PRUSSIA, Pennsylvania-Protarga, Inc. has received comments from the FDA that allow it to proceed with two separate phase III clinical studies of its new cancer drug Taxoprexin Injection (DHA-pacli-taxel) for the treatment of metastatic melanoma and pancreatic cancer. Taxoprexin is made by linking the fatty acid docosahexaenoic acid (DHA) to paclitaxel, the company said in a news release.

KING OF PRUSSIA, Pennsylvania—Protarga, Inc. has received comments from the FDA that allow it to proceed with two separate phase III clinical studies of its new cancer drug Taxoprexin Injection (DHA-pacli-taxel) for the treatment of metastatic melanoma and pancreatic cancer. Taxoprexin is made by linking the fatty acid docosahexaenoic acid (DHA) to paclitaxel, the company said in a news release.

Articles in this issue
Zoledronic Acid Reduces SREs in Solid Tumors
Study Supports Wider Use of SLN Biopsy in Breast Cancer
Minorities Less Likely Than Whites to Receive Good Pain Care
Polyglutamate-Paclitaxel Controls Recurrent Ovarian Cancer
9cRA Shown to Reverse Premaliagnant Changes in Ex-Smokers
FDA Names New ODAC Chair
Neoadjuvant Weekly Paclitaxel Effective in Advanced Breast Cancer
Docetaxel Plus Gemcitabine Promising in Advanced Pancreatic Cancer
Polysaccharides Unique Targets for Immunotherapy
Genetic Fingerprinting Shows Distinct Sarcoma Subsets
Education on Increased ICP Reduces Nursing ‘Headache’
NCI Begins Trial of Spiral CT vs X-rays as a Screening Test
Good But Short-Lived Responses to Rituximab in LPHD
ODAC Supports Use of Iressa for Third-Line Therapy of NSCLC
Subcutaneous Alemtuzumab Produces High Complete Response Rate in Untreated CLL
Related Videos
Immunotherapy may be an “elegant” method of managing colorectal cancer, says Gregory Charak, MD.
Administering neoadjuvant therapy to patients with colorectal cancer may help surgical oncologists attain a negative-margin resection.
Increasing screening for younger individuals who are at risk of colorectal cancer may help mitigate the rising early incidence of this disease.
Laparoscopy may reduce the degree of pain or length of hospital stay compared with open surgery for patients with colorectal cancer.
Rahul Gosain, MD; Sam Klempner, MD; and Rohit Gosain, MD, presenting slides
Rahul Gosain, MD; Sam Klempner, MD; and Rohit Gosain, MD, presenting slides
Rahul Gosain, MD; Sam Klempner, MD; and Rohit Gosain, MD, presenting slides
Rahul Gosain, MD; Sam Klempner, MD; and Rohit Gosain, MD, presenting slides
Rahul Gosain, MD; Sam Klempner, MD; and Rohit Gosain, MD, presenting slides
Tailoring neoadjuvant therapy regimens for patients with mismatch repair deficient gastroesophageal cancer represents a future step in terms of research.
Related Content
The phase 3 KeyVibe-010 trial is unlikely to meet its primary end point of recurrence-free survival due to a high rate of treatment discontinuation.

Investigators Discontinue Vibostolimab Combo in Resected Melanoma Trial

May 14th 2024
Article

The phase 3 KeyVibe-010 trial is unlikely to meet its primary end point of recurrence-free survival due to a high rate of treatment discontinuation.

Experts discuss findings related to gastrointestinal cancer outcomes as well as treatment inequalities presented at the 2024 SSO Annual Meeting.

Surgeons Talk Key Treatment and Institutional Advances Across Oncology Care

April 15th 2024
Podcast

Experts discuss findings related to gastrointestinal cancer outcomes as well as treatment inequalities presented at the 2024 SSO Annual Meeting.

Data from the phase 3 CRC-PREVENT trial support the sensitivity of ColoSense in the detection of colorectal cancer.

FDA Approves Noninvasive Stool RNA Test for Colorectal Cancer Screening

May 7th 2024
Article

Data from the phase 3 CRC-PREVENT trial support the sensitivity of ColoSense in the detection of colorectal cancer.

Diane M. Simeone, MD highlights the importance of multidisciplinary care, surgical practices, and early detection in pancreatic cancer care.

Diane M. Simeone, MD “Thrilled” To Be UCSD Moores Cancer Center Director

February 26th 2024
Podcast

Diane M. Simeone, MD highlights the importance of multidisciplinary care, surgical practices, and early detection in pancreatic cancer care.

CheckMate-8HW assessed the efficacy of first-line nivolumab plus ipilimumab in patients with MSI-H/dMMR metastatic colorectal cancer.

Nivolumab/Ipilimumab Receive Type II Validation by EMA in MSI-H/dMMR mCRC

May 6th 2024
Article

CheckMate-8HW assessed the efficacy of first-line nivolumab plus ipilimumab in patients with MSI-H/dMMR metastatic colorectal cancer.

The primary end point of overall survival was met in the KEYNOTE-811 trial assessing pembrolizumab in HER2-positive gastrointestinal cancer.

Pembrolizumab Combo Yields Significant OS in HER2+ Gastric/GEJ Cancer

May 2nd 2024
Article

The primary end point of overall survival was met in the KEYNOTE-811 trial assessing pembrolizumab in HER2-positive gastrointestinal cancer.